Business Context and Reporting Period
This Form 8-K Current Report was filed by Protara Therapeutics, Inc. on December 3, 2025. The filing discloses updated interim data from the Phase 2 open-label ADVANCED-2 Trial of TARA-002 for non-muscle invasive bladder cancer (NMIBC) and provides a regulatory update regarding the U.S. Food and Drug Administration (FDA).
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and regulatory developments.
Material Changes and Clinical Results
The primary material event is the presentation of updated interim data from the ADVANCED-2 Trial in BCG-Naïve NMIBC patients. Key efficacy results as of the November 7, 2025 data cutoff include:
- Study Population: 31 patients received at least one dose; 29 were evaluable for efficacy.
- Complete Response (CR) Rates:
- Overall CR rate at any time: 72% (21/29).
- CR rate at six months: 69% (18/26).
- CR rate at 12 months: 50% (7/14).
- Response Durability: Among initial responders, 88% maintained response at six months and 100% at 12 months.
- Re-induction Success: 80% of re-induced patients converted to CR at six months, with 100% of those maintaining CR at 12 months.
- Safety Profile: Most treatment-related adverse events (TRAEs) were Grade 1 and transient. No Grade 3 or greater TRAEs were reported, and no patients discontinued due to TRAEs. Common TRAEs included dysuria (13%), fatigue (13%), and hematuria (6%).
Regulatory Outlook and Management Commentary
Protara remains in dialogue with the FDA regarding an expanded registrational path for TARA-002 beyond the BCG-Unresponsive population. Key regulatory developments include:
- BCG-Naïve Pathway: The FDA has provided written feedback supporting a controlled trial design in BCG-Naïve patients.
- Comparator: The FDA agreed that BCG is not required as a comparator; intravesical chemotherapy is acceptable.
- Endpoints: The FDA is aligned with the primary endpoint of CR rate at month 6, with duration of response as a key secondary endpoint.
- BCG-Exposed Patients: The Company is engaging the FDA to determine how to include BCG-Exposed patients in clinical trials.
Management highlighted that the results demonstrate meaningful and durable activity, supporting TARA-002's potential as a mainstay in the NMIBC treatment landscape.
Investor Verification Checklist
- Verify the full text of the Investor Presentation (Exhibit 99.1) and Press Release (Exhibit 99.2) for detailed statistical analysis.
- Review the Poster Presentation (Exhibit 99.3) for granular data on the 31-patient cohort.
- Monitor future filings for the specific design and timeline of the FDA-agreed controlled trial in BCG-Naïve patients.
- Assess the Company's cash runway and financing needs, as this filing does not disclose current liquidity levels.
- Track the status of the FDA engagement regarding the inclusion of BCG-Exposed patients.